亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Trends in the Characteristics, Treatment, and Outcomes of Rectal Adenocarcinoma in the US From 2004 to 2019

医学 结直肠癌 腺癌 回顾性队列研究 内科学 癌症
作者
Sameh Hany Emile,Nir Horesh,Michael R. Freund,Zoe Garoufalia,Rachel Gefen,Emanuela Silva‐Alvarenga,David J. Maron,Giovanna Dasilva,Steven D. Wexner
出处
期刊:JAMA Oncology [American Medical Association]
卷期号:9 (3): 355-355 被引量:24
标识
DOI:10.1001/jamaoncol.2022.6116
摘要

Rectal cancer management has significantly evolved over the last 2 decades.This study aimed to evaluate trends in the characteristics, treatment, and outcomes of rectal adenocarcinoma across 16 years.This retrospective, observational case series study used data from the National Cancer Database (NCDB) to evaluate patients diagnosed with rectal adenocarcinoma from 2004 through 2019. Data analysis was performed from March to May 2022.Trends in the treatment and outcomes of rectal adenocarcinoma in the US between 2004 and 2019 were explored. This period was subdivided into 4 equal periods: 2004-2007, 2008-2011, 2012-2015, and 2016-2019.Patient and tumor characteristics, treatments, short-term outcomes, and overall survival.A total of 318 548 patients diagnosed with rectal adenocarcinoma were included in the analysis, 191 369 (60.1%) of whom were males and 127 179 (39.9%%) were females. The mean (SD) age of the patients was 63.5 (13.4) years, and 46 824 patients (14.8%) were younger than 50 years. Among the patients, 10 859 (3.4%) were of Asian race and ethnicity, 28 464 (8.9%) were Black, and 271 236 (85.1%) were White. The percentage of patients younger than 50 years who were diagnosed with rectal cancer increased by 1.5%, from 13.9% in period 1 to 15.4% in period 4. Patients in the last period (2016-2019) presented more often with stages III (36.2% vs 30.2% vs 25.0% vs 23.4%; P < .001) and IV (21.5% vs 19.3% vs 18.1% vs 18.6%; P < .001) disease compared with those in the remaining 3 periods. The use of chemotherapy (36.8% vs 48.1% vs 49.1% vs 47.0%; P < .001) and immunotherapy (0.4% vs 0.2% vs 3.5% vs 6.5%; P < .001) significantly increased across the 4 periods. Although neoadjuvant radiotherapy was used more often across the periods studied (28.6% in period 1 to 34.3% in period 4), the use of adjuvant radiotherapy was reduced by half (12.9% to 6.0%). The median (IQR) time from diagnosis to definitive surgery increased from 95 (15-126) days in period 1 to 128 (47-158) days in period 4. The rate of use of open surgery decreased by half (60.1% in period 2 to 30.1% in period 4), and the use of robotic surgery significantly increased (5.2% in period 2 to 28.4% in period 4). The conversion rate was significantly reduced (11.2% in period 2 to 7.3% in period 4) and the median (IQR) hospital stay decreased by 2 days, from 6 (3-9) days to 4 (2-7) days. The median (IQR) overall survival significantly increased across the periods (from 83.1 months [95% CI, 81.8-84.6 months] in period 1 to 92.1 months [95% CI, 90.2-93.6 months] in period 3; P < .001).The findings of this case series study suggest a treatment trend of increased use of chemotherapy, immunotherapy, sphincter-saving surgery, and minimally invasive surgery. In addition, the time between diagnosis and definitive surgery increased by a median of 33 days. This treatment trend was associated with a significant improvement in the overall survival, reduction in the conversion rate by 3.9%, and a 2-day shorter hospital stay. These findings have major clinical relevance to the management of rectal cancer. The improvements seen in short-term outcomes and survival of patients diagnosed with rectal cancer can probably be attributed to the treatment trends observed. Continued improvement in outcomes warrant further updates in treatments.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
小杜发布了新的文献求助10
12秒前
jason完成签到 ,获得积分10
27秒前
在水一方应助小杜采纳,获得10
42秒前
53秒前
爱静静举报小趴蔡求助涉嫌违规
1分钟前
李剑鸿发布了新的文献求助30
2分钟前
李剑鸿发布了新的文献求助30
2分钟前
Hello应助Grayball采纳,获得30
2分钟前
3分钟前
3分钟前
Grayball发布了新的文献求助30
3分钟前
4分钟前
Fox完成签到 ,获得积分10
5分钟前
Magali发布了新的文献求助10
5分钟前
Legoxpy完成签到,获得积分20
5分钟前
鬼见愁应助科研通管家采纳,获得20
5分钟前
7分钟前
爱静静完成签到,获得积分0
8分钟前
年鱼精完成签到 ,获得积分10
8分钟前
远方关注了科研通微信公众号
8分钟前
9分钟前
Magali发布了新的文献求助30
9分钟前
9分钟前
11分钟前
耶嘿发布了新的文献求助20
11分钟前
Raunio完成签到,获得积分10
11分钟前
李剑鸿发布了新的文献求助500
12分钟前
和谐板栗完成签到 ,获得积分10
12分钟前
12分钟前
李伟发布了新的文献求助10
12分钟前
科研通AI2S应助李伟采纳,获得10
12分钟前
13分钟前
13分钟前
13分钟前
13分钟前
小杜发布了新的文献求助10
13分钟前
赘婿应助科研通管家采纳,获得10
13分钟前
大模型应助兴奋的嘉懿采纳,获得10
14分钟前
所所应助Billy采纳,获得10
14分钟前
14分钟前
高分求助中
Evolution 10000
Sustainability in Tides Chemistry 2800
The Young builders of New china : the visit of the delegation of the WFDY to the Chinese People's Republic 1000
юрские динозавры восточного забайкалья 800
English Wealden Fossils 700
叶剑英与华南分局档案史料 500
Foreign Policy of the French Second Empire: A Bibliography 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3146739
求助须知:如何正确求助?哪些是违规求助? 2798045
关于积分的说明 7826565
捐赠科研通 2454548
什么是DOI,文献DOI怎么找? 1306376
科研通“疑难数据库(出版商)”最低求助积分说明 627708
版权声明 601527